Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition?

Diabetic Medicine

Volumn 16, Issue 8, 1999, Pages 663-669

  Moro, Ermanno ^a   Alessandrini, P ^a   Zambon, C ^a   Pianetti, S ^a   Pais, M ^a   Cazzolato, G ^a   Bittolo Bon, G ^a  

^a Venice General Hospital   (Italy)

Author keywords

Apolipoprotein B; Glycation; Low density lipoproteins; Oxidation; Type 2 diabetes mellitus

Indexed keywords

ALKADIENE; APOLIPOPROTEIN B; COPPER ION; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLYCATION; HUMAN; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS;

AGED; ANTIBODIES, MONOCLONAL; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FRUCTOSAMINE; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; REFERENCE VALUES; REGRESSION ANALYSIS; TRIGLYCERIDES; VITAMIN E;

EID: 0032725575     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00136.x     Document Type: Article

References (43)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.
2. Steinbrecher UP, Witzum JL. Glycosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33: 130-134.
3. Witzum JL, Mahoney EM, Branks MJ, Fischer M, Elam R, Steinberg D. Nonenzymatic glycosylation of low-density lipoproteins alters its biological activity. Diabetes 1982; 31: 283-291.
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol: modifications of low-density lipoproteins that increased its atherogenicity. N Engl J Med 1989; 320: 915-924.
5. Witzum JL, Steinberg D. Role of oxidised low-density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792.
6. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witzum JL. Glycosylation of low-density lipoproteins enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 37: 1988: 550-557.
7. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation: role in the pathogenesis of diabetic complication. Clin Chem 1986; 32: B37-B41.
8. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissues and the biochemical basis of diabetes complications. N Engl J Med 1988; 318: 1315-1321.
9. Baynes JW. The role of oxidative stress in the development of complications in diabetes. Diabetes 1991; 40: 405-412.
10. Lyons TL. Oxidised LDL: a role in the pathogenesis of atherosclerosis in diabetes. Diabetic Med 1991; 8: 411-419.
11. Yoshida H, Ishikawa T, Nakamura H. Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. Arterioscler Tromb Vasc Biol 1997; 17: 1438-1446.
12. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
13. Gugliucci Creriche A, Stahl AJC. Glycation and oxidation of human low density lipoproteins reduces heparin binding and modifies charge. Scand J Clin Lab Invest 1993; 53: 125-132.
14. Avogaro P, Bittolo-Bon G, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988; 8: 79-87.
15. Avogaro P, Cazzolato G, Bittolo-Bon G. Some questions concerning a small, more electronegative LDL circulating in human plasma, Atherosclerosis 1991; 91: 163-171.
16. Hodis HN, Kramsch DM, Avogaro P, Bittolo Bon G, Cazzolato G, Hwang J et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidised low density lipoprotein. J Lipid Res 1994; 35: 669-677.
17. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1056.
18. Lowry OH, Rosenbourg NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem 1951; 193: 165-167.
19. Kostner GM, Avogaro P, Bittolo-Bon G, Cazzolato G, Quinci GB. Determination of high-density lipoproteins: screening methods compared. Clin Chem 1979; 25: 939-942.
20. Lehman S, Martin HL. Improved direct determination of alpha- and gamma-tocopherols in plasma and platelets in liquid chromatography, with fluorescence detection. Clin Chem 1979; 28: 1784-1788.
21. Yagi K. Assay for serum lipid peroxide level and its clinical significance. In Yagi K ed. Lipid Peroxides in Biology and Medicine. New York: Academic Press, 1985: 223-242.
22. Cazzolato G, Avogaro P, Bittolo-Bon G. Characterisation of a more electronegatively charged LDL subtraction by ion exchange HPLC. Free Rad Biol Med 1991; 11: 247-253.
23. Shea EA, Cohen MP. Immunologie detection and measurement of glycated apolipoprotein B with site specific monoclonal antibodies. J Imunol Meth 1993; 162: 85-95.
24. Esterbauer H, Striegl G, Pukl H, Rotheneder M. Continuous monitoring if in vitro oxidation of human LDL. Free Radic Res Commun 1989; 6: 67-75.
25. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983; 52: 223-261.
26. Sasaki J, Cottam GL. Glycosylation of LDL decreases its ability to interact with high affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vitro. Biochim Biophys Acta 1982; 713: 199-205.
27. Lyons TJ, Baynes JW, Patrick JS, Colwell JA, Lopes-Virella MF. Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia 1986; 29: 685-689.
28. Kleir RL, Laimins M, Lopes-Virella MF. Isolisation, characterisation and metabolism of the glycated and non glycated subfractions of low-density lipoproteins isolated from type I diabetic patients and non diabetic subjects. Diabetes 1985; 44: 1093-98.
29. Kobayashi K, Ogasahara N, Sakoguchi T, Kimura M, Taniuchi K, Matsuoka A. Agarose gel electrophoresis with nitrobluetetrazolium coloration for determination of glycated lipoproteins in serum from diabetics. Clin Chem 1990; 36: 65-69.
30. Sanchez-Quesada JL, Perez A, Caixas A, Ordonmez-Llanos J, Payés A, Gonzalcs-Sastre F et al. Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. Diabetologia 1996; 1469-1476.
31. Gillar YP, Monboisse JC, Maquart FX. Glycation of proteins as a source of superoxide. Diabetes Metab 1998; 14: 25-30.
32. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Comm 1990; 173: 932-937.
33. Wolf SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'Autoxidative glycosylation' in diabetes. Biochem J 1987; 245: 243-250.
34. Hunt JV, Dean RT, Wolf SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes and ageing. Biochem J 1988; 256: 205-212.
35. Sato Y, Hotta N, Sakamoto N, Matasuoka S, Ohishi N, Yagi K. Lipid peroxide level in plasma of diabetic patients. Biochem Med 1979; 21: 104-107.
36. Velasquez E, Winocour PH, Kesteven P, Alberti KG, Laker MF. Relation of lipid peroxides to macrovascular disease in Type 2 diabetes. Diabetic Med 1991; 8: 752-758.
37. Bowie A, Owens D, Collins P, Johnson A,Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993; 102: 63-67.
38. Kobayashi K, Watanabe J, Omeda F, Nawata H. Glycation accelerated the oxidation of low density lipoproteins by copper ions. Endocrine J 1995; 42: 461-465.
39. Babiy AV, Gebicki JM, Sullivan DR, Willey K. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation. Biochem Pharmacol 1992; 43: 995-1000.
40. Reaven PD, Herold DA, Barnett J, Edelman S. Effect of vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subtractions to oxidation and on protein glycation in NIDDM. Diabetes Care 1995; 18: 807-816.
41. Sevanian A, Hwuang J, Hodis H, Cazzolato G, Avogaro P, Bittolo Bon G. Contribution of in vivo oxidised LDL to LDL oxidation and its association with dense LDL subpopulations. Atheros Thromb Vasc Biol 1996; 16: 784-793.
42. Mazzetti A, La Penna D, Pierdomenico SD, Colafiore AM, Costantini F, Riario-Sforza G et al. Vitamin E, C, and lipid peroxidation in plasma and arterial tissues of smokers and non-smokers. Atherosclerosis 1995; 112: 91-99.
43. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.